Quarterly Results
LQDA Earnings Forecast
Looking ahead, LQDA remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 80.72M and an EPS of 0.20.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 104.82%, while EPS estimates have been Revise Downward by -50.21%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 102.98% . These revisions correlate with a 55.13% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in LQDA long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how LQDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LQDA sees a -3.64% change in stock price 10 days leading up to the earnings, and a +0.11% change 10 days following the report. On the earnings day itself, the stock moves by +4.19%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 10.67% on the day following the earnings release and then changed by 12.61% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of LQDA's latest earnings report for FY2025Q3?
LQDA reported its FY2025Q3 earnings on 2025-11-03, showcasing a revenue of 54.34M against an estimate of 19.46M, resulting in a 179.22% surprise. The EPS was -0.04, surpassing the expected -0.45 by 91.11% . The stock experienced a 3.53% price change on the earnings day and a 5.09% change over the next five days, reflecting market reactions to the results.
How did LQDA's stock price react after the FY2025Q3 earnings release?
Following LQDA's FY2025Q3 earnings announcement on 2025-11-03, the stock price moved by 3.53% on the day of the release. Over the subsequent five days, it saw a 5.09% change. Historically, LQDA's stock price tends to shift by an average of -3.64% in the 10 days leading up to earnings and +0.11% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for LQDA for 2025/Q4?
For 2025/Q4, analysts estimate LQDA’s annual revenue to reach 80.72M, while the EPS is projected at 0.20. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 104.82% and EPS estimates Revise Upward by 102.98% over the past three months, indicating analyst expectation in the company’s performance.
How does LQDA's stock price correlate with earnings forecast revisions?
The correlation between LQDA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 104.82%, while EPS estimates moved Revise Upward by 102.98% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from LQDA's next earnings report?
Based on historical trends, LQDA's stock price typically moves by -3.64% in the 10 days before its earnings and +0.11% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.20 and revenue of 80.72M.
What is the sentiment in Liquidia Corp (LQDA) Q3 2025 Earnings Call Summary?
The earnings call highlights strong YUTREPIA adoption, positive cash flow, and profitability ahead of schedule. Although there are execution and litigation risks, the company's strategic plans and payer coverage expansion indicate growth potential. The Q&A session shows positive sentiment from analysts, with management addressing concerns effectively. Overall, the positive financial performance and market strategy outweigh the potential risks, suggesting a stock price increase.

